Patents by Inventor Kavita Inamdar

Kavita Inamdar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for manufacturing sterile brinzolamide ophthalmic suspension
    Patent number: 9649319
    Abstract: The present invention relates to a process for manufacturing sterile Brinzolamide Ophthalmic Suspension. Specifically, the present invention relates to a process for manufacturing sterile ophthalmic suspension comprising Brinzolamide sterilized by Dry Heat Sterilization and pharmaceutical suspension obtained by using the said sterilized Brinzolamide. The present invention also relates to a process of manufacturing sterile ophthalmic suspension comprising combination of Brinzolamide sterilized by Dry Heat Sterilization and beta blocker.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: May 16, 2017
    Assignee: INDOCO REMEDIES LIMITED
    Inventors: Aditi Panandikar, Sundeep Bambolkar, Kavita Inamdar, Sapna Ramesh, Pradnya Bagde
  • Pharmaceutical composition of linezolid
    Patent number: 9492459
    Abstract: The present invention relates to a novel pharmaceutical composition of Linezolid. The present invention relates to a novel pharmaceutical composition comprising Linezolid Form III along with pharmaceutically acceptable excipients and a process to prepare the said composition. The present invention relates to an oral dosage forms for the treatment of severe infections caused by Gram-positive bacteria.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: November 15, 2016
    Assignee: Indoco Remedies Limited
    Inventors: Aditi Panandikar, Sundeep Bambolkar, Kavita Inamdar, Sapna Ramesh, Amol Burkul, Nasir Shaikh
  • PROCESS FOR MANUFACTURING STERILE BRINZOLAMIDE OPHTHALMIC SUSPENSION
    Publication number: 20150250796
    Abstract: The present invention relates to a process for manufacturing sterile Brinzolamide Ophthalmic Suspension. Specifically, the present invention relates to a process for manufacturing sterile ophthalmic suspension comprising Brinzolamide sterilized by Dry Heat Sterilization and pharmaceutical suspension obtained by using the said sterilized Brinzolamide. The present invention also relates to a process of manufacturing sterile ophthalmic suspension comprising combination of Brinzolamide sterilized by Dry Heat Sterilization and beta blocker.
    Type: Application
    Filed: October 8, 2013
    Publication date: September 10, 2015
    Applicant: INDOCO REMEDIES LIMITED
    Inventors: Aditi Panandikar, Sundeep Bambolkar, Kavita Inamdar, Sapna Ramesh, Pradnya Bagde
  • NOVEL PHARMACEUTICAL COMPOSITION OF LINEZOLID
    Publication number: 20150093437
    Abstract: The present invention relates to a novel pharmaceutical composition of Linezolid. The present invention relates to a novel pharmaceutical composition comprising Linezolid Form III along with pharmaceutically acceptable excipients and a process to prepare the said composition. The present invention relates to an oral dosage forms for the treatment of severe infections caused by Gram-positive bacteria.
    Type: Application
    Filed: August 2, 2013
    Publication date: April 2, 2015
    Inventors: Aditi Panandikar, Sundeep Bambolkar, Kavita Inamdar, Sapna Ramesh, Amol Burkul, Nasir Shaikh
  • Sustained release tablet containing hydrocolloid and cellulose ether
    Patent number: 6416786
    Abstract: The present invention is directed to a solid sustained release pharmaceutical tablet for administering to a host, comprising a therapeutically effective amount of a pharmaceutically active ingredient and a sustained release carrier therefor, said sustained release carrier comprising (a) a hydrocolloid selected from the group consisting of xanthan gum, guar gum, and alginic acid or a pharmaceutically acceptable salt thereof, and (b) a cellulose ether, said hydrocolloid and cellulose ether being present in synergistic effective amounts to retard release of said pharmaceutically active ingredient, said hydrocolloid being present in amount ranging from about 0.3% to about 7.0% by weight of the tablet and said cellulose ether being present in an amount ranging from 3% to about 20% of said tablet, and said cellulose ether being present in said carrier in amounts equal to or greater than 33% by weight and said carrier being present in amounts less than 35% by weight of said tablet.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: July 9, 2002
    Assignee: Nostrum Pharmaceuticals, Inc.
    Inventors: Nirmal Mulye, Kavita Inamdar